Celltrion

This study tests a new medicine called CT-P55 against the approved drug Cosentyx in 153 adults with moderate to severe plaque psoriasis. The goal is to see if CT-P55 works as well and is as safe. Participants must have had psoriasis for at least 6 months and cannot have used cert…

This study watches for side effects in 881 people with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or psoriasis who receive Remsima under the skin. It aims to see how safe the injection is over time. Participants must have active disease that didn't respond…

This early-stage study is testing two experimental drugs (L03RD1 and L03RD2) for type 2 diabetes in 48 healthy adults aged 19-55. The goal is to see how the body processes these drugs and check for safety. Participants will receive single doses in a crossover design. This study d…

This study tests whether a new biosimilar medicine (CT-P52) works like the approved drug Taltz in the body. About 218 healthy adults aged 19 to 55 will receive a single dose of either CT-P52 or Taltz. Researchers will measure how the drug levels and safety compare between the two…

This study tests two different devices (an auto-injector and a pre-filled syringe) for giving a single dose of the drug CT-P52. It involves 218 healthy men aged 19 to 55. The goal is to see if both methods deliver the drug into the body in a similar way and are safe.